Compounded GLP-1 medicines, such as compounded semaglutide and tirzepatide, are prepared by a pharmacy for an individual patient and are not FDA-approved, so FDA has not reviewed them for safety, effectiveness or quality.
If one is prescribed, you should know exactly what it contains, which licensed pharmacy made it and how it differs from Wegovy® or Zepbound®.
This guide explains how compounding works, the difference between 503A and 503B pharmacies, the 2026 rules after the shortages, the safety concerns FDA has reported and what to verify before treatment.
| Feature | FDA-approved brand | Compounded medication |
|---|---|---|
| FDA premarket review | Product application reviewed before approval | No FDA review before it reaches patients |
| Label | FDA-approved prescribing information | Pharmacy directions for one patient, not a brand label |
| Who makes it | Approved manufacturer under product controls | Licensed pharmacy under federal and state rules |
| Clinical basis | The approved label or a physician’s judgment | A prescription for an identified patient |
| Marketing | Claims must match the label | Must disclose that it is not FDA-approved |
| Identity | Brand, dosage form and application are explicit | Substance, form, concentration and pharmacy must be named |
In this article
Why Do People Choose Compounded GLP-1s?
Cost is the main reason. Brand-name GLP-1 medicines can be expensive without insurance coverage, and compounded versions have often been offered at a lower price.
The trade-off is that the product has not gone through FDA review, and quality depends on the pharmacy that made it. That makes the prescriber’s choice of pharmacy, and your understanding of what you are receiving, especially important.
Compounded semaglutide and tirzepatide
What does pharmacy compounding mean?
Drug compounding combines, mixes or alters ingredients to create a medicine for an individual patient. It serves a legitimate role when an approved product does not meet a patient’s documented need, such as an allergy to an inactive ingredient or another patient-specific difference.
Federal law sets the boundaries. A pharmacy may not treat compounding as a general route to mass-produce copies of commercially available approved drugs. The patient’s need must be real, and the prescriber documents it.
FDA approval, 503A pharmacies and 503B facilities
How does a compounded medication differ from an FDA-approved drug?
An approved drug has passed FDA review of a specific product application. The agency evaluates the proposed indication, label, manufacturing controls and supporting data before approval.
FDA does not pre-review each compounded preparation for safety, effectiveness or quality. There is no agency-reviewed package insert, and a brand’s insert cannot be borrowed.
What is the difference between 503A and 503B?
Section 503A generally covers patient-specific compounding by state-licensed pharmacies or physicians. Section 503B covers registered outsourcing facilities with different federal requirements, including current good manufacturing practices.
The categories are not interchangeable quality badges. A 503A pharmacy should not claim the manufacturing standard that applies to a 503B outsourcing facility simply because both prepare drugs. Status should be verified, not inferred from a logo.
Drug shortages and compounding rules in 2026
Why did the drug shortages matter?
Federal law restricts pharmacies from regularly making drugs that are essentially copies of commercially available approved products. During an FDA-listed shortage, the commercially available analysis changes, which opened temporary room to compound widely used GLP-1 drugs.
FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. It then set transition periods for each pharmacy category before ending temporary enforcement discretion. Those periods have closed. Litigation and later enforcement statements should be read against their dates.
A historical shortage is not a standing permission. Compounding now rests on the patient-specific pathway.
What does “essentially a copy” mean?
Under section 503A, a compounded drug is not treated as a copy of an approved product when a change made for an identified patient produces a significant difference for that patient, as the prescriber determines. The statute also limits regular or inordinate preparation of copies.
Additives and new forms do not settle that question alone. Adding a vitamin, making a modest strength change or switching to a liquid or tablet does not by itself establish a significant difference. FDA has also raised concerns about unapproved salt forms and nonstandard presentations sold online.
The prescriber must make and document the patient-specific determination. “Personalized” is a clinical finding, not a slogan.
Ingredient identity, dosing errors and safety
What safety concerns has FDA reported?
FDA has described dosing errors, adverse events, fraudulent labels, incorrect or unapproved chemical forms and quality concerns with unapproved GLP-1 products. Some reports involved patients drawing incorrect amounts from multi-dose vials or misreading concentrations.
The active ingredient carries its known risks whatever the source. For semaglutide and tirzepatide, those include digestive effects, pancreatitis, gallbladder disease and kidney injury linked to dehydration. The physician reviews them before prescribing and at every follow-up.
Severe vomiting, dehydration, persistent abdominal pain, allergic symptoms or another serious reaction need prompt clinical direction. The compounded GLP-1 safety information sets out the risks in full.
Why is product identity so important?
Patients and clinicians should know:
- The active substance and chemical form
- The concentration and inactive ingredients
- The pharmacy that made it
- The beyond-use date
- Storage requirements and directions
A vial without complete labeling makes adverse-event investigation and continuity harder.
The pharmacy should be licensed for the relevant activity and jurisdiction. The prescriber should be able to explain why that exact preparation fits the patient. Ask how concentration is expressed and whether the supplied device matches the written directions. Ambiguity is not personalization.
Product labels, marketing and prescriptions
Can an approved brand's label be reused?
No. The Wegovy® and Zepbound® labels describe those specific products. A compounded semaglutide or tirzepatide has not been reviewed as the branded drug. The brand’s approval, device claims, trial outcomes and dosing evidence do not transfer to it.
The Wegovy and Zepbound label comparison covers the two approved products on their own terms.
What marketing claims has FDA challenged?
FDA has warned against claims that present a compounded product as FDA-approved, as the brand itself, or as carrying a brand’s clinical evidence. Language that treats access, approval or prescribing as predetermined can also obscure the prescriber’s independent role.
On March 3, 2026, FDA announced 30 warning letters concerning false or misleading compounded GLP-1 marketing. The announcement addressed product-status claims and unclear sourcing.
Does a prescription settle every issue?
No. A valid prescription is necessary in patient-specific pathways, but legality also depends on the product, the preparer, statutory conditions, state law and whether the preparation is essentially a copy. The pharmacy and the prescriber hold separate responsibilities.
The prescribing rationale must apply to the individual patient. A standard website checkbox cannot establish it.
Pharmacy questions and the Atlas HRT process
What should a patient verify?
Ask for the preparer’s legal name and license, the exact product description, which statutory pathway applies and how adverse events or recalls are handled. Do not rely on social-media messages, color descriptions or copied brand instructions.
| Check | What to look for |
|---|---|
| Pharmacy | Legal name and state license, verifiable through the state board |
| Substance | Exact active ingredient and chemical form |
| Directions | Concentration and supplied device match the written directions |
| Prescription | Written for you by a physician who reviewed your health |
| Safety reporting | How reactions and recalls are reported and handled |
| Records | The label and lot information, kept for reference |
How does Atlas HRT coordinate a compounded prescription?
Through Atlas HRT, an independent Florida-licensed physician decides whether compounded semaglutide or tirzepatide, Zepbound, Wegovy or no medication fits, and a licensed compounding pharmacy prepares and ships any compounded prescription. Compounded medications are prepared by a licensed pharmacy for an individual patient and are not FDA-approved. Atlas HRT does not compound or dispense medication.
The physician reviews your health history, current medicines and goals before any decision. Follow-up visits review tolerability, side effects and whether the medication still fits. Your wellness consultant explains the next steps but does not decide eligibility or choose a product. Keep the pharmacy label, which names the preparation, its concentration and the directions.
We think patients deserve plain answers about compounded GLP-1s rather than marketing. They can be a reasonable option when prescribed for an individual reason and made by a properly licensed pharmacy. They are not the same as Wegovy® or Zepbound®, and nobody should present them as if they were.
Common questions
Is compounded semaglutide or tirzepatide FDA-approved?
No. FDA does not review or approve a compounded preparation before it reaches patients, as it does for a brand-name drug application.
How does a compounded GLP-1 relate to a brand-name drug?
Compounded medications are not generic versions of, and have not been shown to be equivalent to, any FDA-approved drug. A brand’s label, trial results and approval do not transfer to them.
Did the national shortages end?
Yes. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025.
Atlas HRT Team
Reviewed by · Last reviewed September 2026Atlas HRT specializes in GLP-1 weight loss treatment, including brand-name and compounded options, for adults in Florida.
Sources
- FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s, U.S. Food and Drug Administration
- FDA compounding questions and answers, U.S. Food and Drug Administration
- FDA concerns with unapproved GLP-1 drugs used for weight loss, U.S. Food and Drug Administration
- Zepbound prescribing information, Eli Lilly; accessed October 10, 2026
